HYPERMARKER is a four-year international research project that received a 10 million euro grant from Horizon Europe and UK Research and Innovation. Starting in January 2023, the project aims to unleash the potential of pharmacometabolics to provide ‘smart’ prescription of antihypertensive therapy, based on large-scale cohorts from 11 European countries, with validation in a randomised control trial. The primary outcome will be a metabolic profile-based clinical decision support tool that uses advanced data analytics and robust AI algorithms to personalise and optimise the choice of blood pressure treatment. As CVDs are prevalent among patients with hypertension, the effectiveness of pharmaceuticals prescribed for hypertension will also be studied in heart failure (HF), acute coronary syndrome (ACS) and atrial fibrillation (AF).
EHN will primarily contribute to Work Package 2 by representing patients’ interests and facilitating patient involvement in the Patient and Public Involvement and Engagement (PPIE) team. The PPIE team will act as patient advocates to ensure ethical data sharing and research activities and provide recommendations to the management team on appropriate data use, data sharing and transparency.
Project Key Facts
Coordinator: University Medical Center Utrecht (UMCU)
Start Date: 1 January 2023
Budget: 10,000,000 €
To learn more about this project, visit the HYPERMARKER LinkedIn page.